Athena patents expiration
1. Fibricor patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7569612 | ATHENA | Methods of use of fenofibric acid |
Aug, 2027
(3 years from now) | |
| US7741373 | ATHENA | Methods of use of fenofibric acid |
Aug, 2027
(3 years from now) | |
| US7915247 | ATHENA | Methods of use of fenofibric acid |
Aug, 2027
(3 years from now) | |
| US7741374 | ATHENA | Methods of use of fenofibric acid |
Aug, 2027
(3 years from now) | |
Drugs and Companies using FENOFIBRIC ACID ingredient
Market Authorisation Date: 14 August, 2009
Treatment: Adjunctive therapy to diet in patients with hyperlipidemias; Adjunctive therapy to diet to patients with hypertriglyceridemia; Adjunctive therapy to diet in patients with mixed dyslipidemia; Adjunctiv...
Dosage: TABLET;ORAL
FIBRICOR family patents
2. Nexiclon Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8337890 | ATHENA | Modified release formulations containing drug-ion exchange resin complexes |
Apr, 2027
(3 years from now) | |
| US8623409 | ATHENA | Clonidine formulation |
Sep, 2031
(7 years from now) | |
Drugs and Companies using CLONIDINE ingredient
Market Authorisation Date: 03 December, 2009
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
NEXICLON XR family patents
3. Qdolo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11103452 | ATHENA | Tramadol hydrochloride solution |
Sep, 2040
(16 years from now) | |
Drugs and Companies using TRAMADOL HYDROCHLORIDE ingredient
Market Authorisation Date: 01 September, 2020
Treatment: Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Dosage: SOLUTION;ORAL
QDOLO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic